Glaxosmithkline Pharmaceuticals Limited

BSE: 500660 NSE: GLAXO
Glaxosmithkline Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24239MH1924PLC001151 Incorporated 13 November 1924 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: GLAXO · BSE: 500660 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹3,821.67 Cr
▲ 1.93% YoY
Computed EBITDA · FY 2026
₹1,454.56 Cr
▲ 9.92% YoY
Net profit · FY 2026
₹1,035.98 Cr
▲ 11.69% YoY
Authorised capital
₹180 Cr
Registered with MCA
Paid-up capital
₹169.41 Cr
Issued & subscribed
Open charges
₹21.87 Cr
Satisfied ₹130 Cr
Company age
102 yrs
Est. 1924
Employees · EPFO
505
Latest available

About Glaxosmithkline Pharmaceuticals Limited

Data last updated: 14 July 2026

Glaxosmithkline Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 13 November 1924, the company has been in operation for over 102 years.

Registered with ROC Mumbai under CIN U24239MH1924PTC001151. Listed on BSE: 500660 and NSE: GLAXO.

Capital: an authorised share capital of ₹180 Cr and a paid-up capital of ₹169.41 Cr. Formerly known as British Drug Houses (India) Private Limited and British Drug Houses (India) Limited. It is led by directors including Subesh Ronald Williams and Renu Sud Karnad.

Last AGM: 27 June 2025. Financial statements filed for year ended 31 March 2025. Office: Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹3,821.67 Cr, a growth of 1.93% compared to the previous year. The net worth stands at ₹2,284.69 Cr (up 17.08% YoY). Total assets are valued at ₹4,323.87 Cr (up 5.25% YoY).

The company has a workforce of approximately 505 employees as per the latest available data.

As per MCA filings, the company has open charges of ₹21.87 Cr and satisfied charges of ₹130 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website india-pharma.gsk.com.

Company Details of Glaxosmithkline Pharmaceuticals Limited
CIN L24239MH1924PLC001151
Registration Number 001151
Incorporation Date 13 November 1924
ROC Mumbai
Listing Status Listed (BSE: 500660, NSE: GLAXO)
Company Status Active
Date of Last AGM 27 June 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Bhushan Arun Akshikar Managing Director Ronojit Biswas Whole-Time Director Subesh Ronald Williams Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    Locked
  • Social Media
  • Registered Address
    Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
  • Industry
    Pharma, Drug Formulation & Development
Company report
Glaxosmithkline Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Glaxosmithkline Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Glaxosmithkline Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has undergone 3 name changes throughout its history. The company was previously known as British Drug Houses (India) Private Limited, British Drug Houses (India) Limited, and Glaxo India Limited. The current legal name is Glaxosmithkline Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Glaxosmithkline Pharmaceuticals Limited Current
British Drug Houses (India) Private Limited Previous
British Drug Houses (India) Limited Previous
Glaxo India Limited Previous

CIN History of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24239MH1924PTC001151. The current CIN is L24239MH1924PLC001151, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239MH1924PLC001151 Current
U24239MH1924PTC001151 Previous

Business Activity of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Glaxosmithkline Pharmaceuticals Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is audited by M/S Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/S Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is currently managed by 8 directors, with 31 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Subesh Ronald Williams Director 07 Apr 2017 9 Years 3 Months Current
Renu Sud Karnad
Also directs: Eih Limited, Hdfc Bank Limited, Hdfc Asset Management Company Limited and 5 more
Director 01 Apr 2019 7 Years 3 Months Current
Sunita Maheshwari
Also directs: Hdfc Bank Limited, Trs Solutions Llp, Rxdx-Samanvay Llp and 5 more
Director 18 May 2020 6 Years 2 Months Current
Manu Anand
Also directs: United Breweries Limited
Director 16 May 2022 4 Years 2 Months Current
Bhushan Arun Akshikar
Also directs: Biddle Sawyer Limited, Organisation Of Pharmaceutical Producers Of India
Managing Director 01 Dec 2022 3 Years 7 Months Current
Somasundaram Palamadairamaswamy
Also directs: Dcb Bank Limited, India International Bullion Exchange Ifsc Limited
Director 26 Mar 2025 1 Years 3 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Glaxosmithkline Pharmaceuticals Limited FY 2026 filings available

Glaxosmithkline Pharmaceuticals Limited reported revenue of ₹3,821.67 Cr (up 1.93% YoY) for FY 2026.

Revenue · FY 2026
₹3,821.67 Cr ▲ 1.93%
Profit · FY 2026
₹1,035.98 Cr ▲ 11.69%
Computed EBITDA · FY 2026
₹1,454.56 Cr ▲ 9.92%
Revenue₹ Cr · Consolidated02,0004,000FY 2020: ₹3,224 Cr3,224FY 2020FY 2021: ₹3,199 Cr · -0.8% YoY3,199-0.8%FY 2021FY 2022: ₹3,278 Cr · +2.5% YoY3,278+2.5%FY 2022FY 2023: ₹3,252 Cr · -0.8% YoY3,252-0.8%FY 2023FY 2024: ₹3,454 Cr · +6.2% YoY3,454+6.2%FY 2024FY 2025: ₹3,749 Cr · +8.6% YoY3,749+8.6%FY 2025FY 2026: ₹3,822 Cr · +1.9% YoY3,822+1.9%FY 2026
Net Profit₹ Cr · Consolidated01,0002,000FY 2020: ₹93 Cr93.2FY 2020FY 2021: ₹358 Cr · +284.3% YoY358+284.3%FY 2021FY 2022: ₹1,695 Cr · +373.2% YoY1,695+373.2%FY 2022FY 2023: ₹611 Cr · -64% YoY611-64%FY 2023FY 2024: ₹590 Cr · -3.4% YoY590-3.4%FY 2024FY 2025: ₹928 Cr · +57.2% YoY928+57.2%FY 2025FY 2026: ₹1,036 Cr · +11.7% YoY1,036+11.7%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹815 Cr · +7% YoY815+7%Q1'25Q2'25: ₹1,011 Cr · +5.6% YoY1,011+5.6%Q2'25Q3'25: ₹949 Cr · +17.9% YoY949+17.9%Q3'25Q4'25: ₹974 Cr · +4.8% YoY974+4.8%Q4'25Q1'26: ₹805 Cr · -1.2% YoY805-1.2%Q1'26Q2'26: ₹980 Cr · -3.1% YoY980-3.1%Q2'26Q3'26: ₹1,041 Cr · +9.7% YoY1,041+9.7%Q3'26Q4'26: ₹995 Cr · +2.1% YoY995+2.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,821.67 Cr ₹3,749.21 Cr ₹3,453.71 Cr ₹3,251.72 Cr ₹3,278.03 Cr ₹3,198.86 Cr ₹3,224.38 Cr
Other Income ₹145.36 Cr ₹145.93 Cr ₹122.59 Cr ₹100.66 Cr ₹75.78 Cr ₹110.58 Cr ₹79.01 Cr
Total Income ₹3,967.03 Cr ₹3,895.14 Cr ₹3,576.3 Cr ₹3,352.38 Cr ₹3,353.81 Cr ₹3,309.44 Cr ₹3,303.39 Cr
Cost of Materials Consumed ₹436.15 Cr ₹499.9 Cr ₹545.17 Cr ₹427.48 Cr ₹611.18 Cr ₹472.02 Cr ₹474.38 Cr
Purchases of Stock-in-Trade ₹910.45 Cr ₹845.11 Cr ₹853.08 Cr ₹788.43 Cr ₹729.44 Cr ₹880.11 Cr ₹868.92 Cr
Changes in Inventories ₹4.46 Cr ₹45.85 Cr -₹63.72 Cr ₹68.96 Cr ₹15.57 Cr -₹39.43 Cr -₹35.43 Cr
Employee Benefit Expense ₹607.25 Cr ₹579.7 Cr ₹624.39 Cr ₹594.99 Cr ₹610.23 Cr ₹614.69 Cr ₹628.55 Cr
Finance Costs ₹2.73 Cr ₹1.31 Cr ₹1.8 Cr ₹1.81 Cr ₹2 Cr ₹3.53 Cr ₹6.34 Cr
Depreciation & Amortisation ₹66.44 Cr ₹66.79 Cr ₹69.68 Cr ₹65.77 Cr ₹68.19 Cr ₹79.28 Cr ₹82.68 Cr
Other Expenses ₹554.16 Cr ₹601.29 Cr ₹586.1 Cr ₹567.57 Cr ₹549.73 Cr ₹576.14 Cr ₹630.71 Cr
Total Expenses ₹2,581.64 Cr ₹2,639.95 Cr ₹2,616.5 Cr ₹2,515.01 Cr ₹2,586.34 Cr ₹2,586.34 Cr ₹2,656.15 Cr
Profit Before Exceptional Items & Tax ₹1,385.39 Cr ₹1,255.19 Cr ₹959.8 Cr ₹837.37 Cr ₹767.47 Cr ₹723.1 Cr ₹647.24 Cr
Exceptional Items ₹20.62 Cr ₹4.69 Cr -₹143.61 Cr -₹97 Lakh ₹11.58 Cr -₹172.6 Cr -₹341.49 Cr
Profit Before Tax ₹1,406.01 Cr ₹1,259.88 Cr ₹816.19 Cr ₹836.4 Cr ₹779.05 Cr ₹550.5 Cr ₹305.75 Cr
Total Tax Expense ₹370.03 Cr ₹332.3 Cr ₹226.23 Cr ₹228.76 Cr ₹398.28 Cr ₹192.35 Cr ₹212.55 Cr
Net Profit ₹1,035.98 Cr ₹927.58 Cr ₹589.96 Cr ₹610.69 Cr ₹1,694.72 Cr ₹358.15 Cr ₹93.2 Cr
  attributable to Owners - ₹0 ₹589.96 Cr ₹610.69 Cr - ₹358.15 Cr -
  attributable to NCI - ₹0 ₹0 ₹0 - ₹0 -
Other Comprehensive Income -₹7.54 Cr -₹2.66 Cr -₹4.17 Cr -₹6.04 Cr -₹1.85 Cr -₹2.05 Cr -₹3.98 Cr
Total Comprehensive Income ₹1,028.44 Cr ₹924.92 Cr ₹585.79 Cr ₹604.65 Cr ₹1,692.87 Cr ₹356.1 Cr ₹89.22 Cr
EBITDA (computed) ₹1,454.56 Cr ₹1,323.29 Cr ₹1,031.28 Cr ₹904.95 Cr ₹837.66 Cr ₹805.91 Cr ₹736.25 Cr
Basic EPS ₹54.52 ₹54.52 ₹34.83 ₹35.87 ₹22.48 ₹21.14 ₹5.50
Diluted EPS ₹54.76 ₹54.76 ₹34.83 ₹35.87 ₹22.48 ₹21.14 ₹5.50
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,323.87 Cr ₹4,108.08 Cr ₹3,556.62 Cr ₹3,326.58 Cr
Non-current Assets ₹539.16 Cr ₹502.19 Cr ₹544.56 Cr ₹618.36 Cr
Current Assets ₹3,784.71 Cr ₹3,605.89 Cr ₹3,012.06 Cr ₹2,708.22 Cr
Property, Plant & Equipment ₹273.51 Cr ₹269.54 Cr ₹296.8 Cr ₹294.81 Cr
Inventories ₹457.55 Cr ₹481.74 Cr ₹525.05 Cr ₹459.97 Cr
Trade Receivables ₹273.11 Cr ₹292.55 Cr ₹222.06 Cr ₹192.38 Cr
Cash & Equivalents ₹1,102.05 Cr ₹538.85 Cr ₹64.17 Cr ₹34.94 Cr
Equity (Net Worth) ₹2,284.69 Cr ₹1,951.31 Cr ₹1,777.64 Cr ₹1,741.28 Cr
Equity Share Capital ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹1,779.11 Cr ₹1,905.17 Cr ₹1,524.95 Cr ₹1,326.36 Cr
Total Liabilities ₹2,039.18 Cr ₹2,156.77 Cr ₹1,778.98 Cr ₹1,585.3 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹903.3 Cr ₹1,289.91 Cr ₹582 Cr ₹484.23 Cr ₹810.74 Cr
Investing Cash Flow ₹396.98 Cr -₹45.81 Cr ₹8.72 Cr ₹807.85 Cr -₹405.5 Cr
Financing Cash Flow -₹737.08 Cr -₹769.42 Cr -₹561.49 Cr -₹1,543.33 Cr -₹524.24 Cr
Capital Expenditure ₹55.28 Cr ₹23.02 Cr ₹31.22 Cr ₹44.04 Cr ₹34.64 Cr
Free Cash Flow (computed) ₹848.02 Cr ₹1,266.89 Cr ₹550.78 Cr ₹440.19 Cr ₹776.1 Cr
Dividends Paid ₹713.97 Cr ₹749.38 Cr ₹541.57 Cr ₹1,525.5 Cr ₹506.64 Cr
Net Change in Cash ₹563.2 Cr ₹474.68 Cr ₹29.23 Cr -₹251.25 Cr -₹119 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹995.3 Cr ₹1,041.26 Cr ₹979.94 Cr ₹805.17 Cr ₹974.37 Cr ₹949.42 Cr ₹1,010.77 Cr ₹814.65 Cr ₹929.8 Cr ₹805.26 Cr ₹956.99 Cr ₹761.66 Cr
Other Income ₹35.95 Cr ₹32.12 Cr ₹33.57 Cr ₹43.72 Cr ₹40.68 Cr ₹35.07 Cr ₹34.54 Cr ₹35.64 Cr ₹29.83 Cr ₹28.11 Cr ₹28.21 Cr ₹36.44 Cr
Total Income ₹1,031.25 Cr ₹1,073.38 Cr ₹1,013.51 Cr ₹848.89 Cr ₹1,015.05 Cr ₹984.49 Cr ₹1,045.31 Cr ₹850.29 Cr ₹959.63 Cr ₹833.37 Cr ₹985.2 Cr ₹798.1 Cr
Cost of Materials Consumed ₹113.06 Cr ₹79.9 Cr ₹115.13 Cr ₹128.06 Cr ₹115.23 Cr ₹97.48 Cr ₹148.96 Cr ₹138.23 Cr ₹204.6 Cr ₹90.95 Cr ₹91.21 Cr ₹158.41 Cr
Purchases of Stock-in-Trade ₹228.4 Cr ₹217.27 Cr ₹232.72 Cr ₹232.06 Cr ₹291.4 Cr ₹164.23 Cr ₹216.74 Cr ₹172.74 Cr ₹255.74 Cr ₹162.52 Cr ₹260.62 Cr ₹174.2 Cr
Changes in Inventories ₹2.54 Cr ₹66.65 Cr ₹7.68 Cr -₹72.41 Cr -₹54.69 Cr ₹97.45 Cr ₹18.79 Cr -₹15.7 Cr -₹93.21 Cr ₹63.37 Cr ₹2.61 Cr -₹36.49 Cr
Employee Benefit Expense ₹164.75 Cr ₹151.88 Cr ₹138.05 Cr ₹152.57 Cr ₹152.97 Cr ₹124.74 Cr ₹150.71 Cr ₹151.28 Cr ₹172.83 Cr ₹141.35 Cr ₹145.21 Cr ₹165 Cr
Finance Costs ₹61 Lakh ₹1.19 Cr ₹51 Lakh ₹42 Lakh ₹58 Lakh ₹9 Lakh ₹27 Lakh ₹37 Lakh ₹77 Lakh ₹32 Lakh ₹43 Lakh ₹28 Lakh
Depreciation & Amortisation ₹13.17 Cr ₹20.32 Cr ₹17.43 Cr ₹15.52 Cr ₹14.72 Cr ₹18.8 Cr ₹16.86 Cr ₹16.41 Cr ₹18.1 Cr ₹17.11 Cr ₹18.11 Cr ₹16.36 Cr
Other Expenses ₹135.62 Cr ₹154.22 Cr ₹150.63 Cr ₹113.69 Cr ₹136.27 Cr ₹173.6 Cr ₹153.86 Cr ₹137.56 Cr ₹132.58 Cr ₹129.01 Cr ₹167.85 Cr ₹156.66 Cr
Total Expenses ₹658.15 Cr ₹691.43 Cr ₹662.15 Cr ₹569.91 Cr ₹656.48 Cr ₹676.39 Cr ₹706.19 Cr ₹600.89 Cr ₹691.41 Cr ₹604.63 Cr ₹686.04 Cr ₹634.42 Cr
Profit Before Exceptional Items & Tax ₹373.1 Cr ₹381.95 Cr ₹351.36 Cr ₹278.98 Cr ₹358.57 Cr ₹308.1 Cr ₹339.12 Cr ₹249.4 Cr ₹268.22 Cr ₹228.74 Cr ₹299.16 Cr ₹163.68 Cr
Exceptional Items ₹0 ₹17.98 Cr ₹2.64 Cr ₹0 ₹0 ₹0 ₹4.69 Cr ₹0 ₹2.4 Cr -₹163.31 Cr ₹0 ₹17.3 Cr
Profit Before Tax ₹373.1 Cr ₹399.93 Cr ₹354 Cr ₹278.98 Cr ₹358.57 Cr ₹308.1 Cr ₹343.81 Cr ₹249.4 Cr ₹270.62 Cr ₹65.43 Cr ₹299.16 Cr ₹180.98 Cr
Total Tax Expense ₹95.24 Cr ₹104.31 Cr ₹96.51 Cr ₹73.97 Cr ₹95.7 Cr ₹78.22 Cr ₹91.31 Cr ₹67.07 Cr ₹76.14 Cr ₹19.71 Cr ₹81.65 Cr ₹48.73 Cr
Net Profit ₹277.86 Cr ₹295.62 Cr ₹257.49 Cr ₹205.01 Cr ₹262.87 Cr ₹229.88 Cr ₹252.5 Cr ₹182.33 Cr ₹194.48 Cr ₹45.72 Cr ₹217.51 Cr ₹132.25 Cr
  attributable to Owners - ₹0 ₹0 ₹0 ₹0 - - ₹0 ₹194.48 Cr ₹45.72 Cr ₹217.51 Cr ₹132.25 Cr
  attributable to NCI - ₹0 ₹0 ₹0 ₹0 - - ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹13.74 Cr ₹6.2 Cr ₹0 ₹0 -₹3.84 Cr ₹1.18 Cr ₹0 ₹0 -₹69 Lakh -₹3.48 Cr ₹0 ₹0
Total Comprehensive Income ₹264.12 Cr ₹301.82 Cr ₹257.49 Cr ₹205.01 Cr ₹259.03 Cr ₹231.06 Cr ₹252.5 Cr ₹182.33 Cr ₹193.79 Cr ₹42.24 Cr ₹217.51 Cr ₹132.25 Cr
EBITDA (computed) ₹386.88 Cr ₹403.46 Cr ₹369.3 Cr ₹294.92 Cr ₹373.87 Cr ₹326.99 Cr ₹356.25 Cr ₹266.18 Cr ₹287.09 Cr ₹246.17 Cr ₹317.7 Cr ₹180.32 Cr
Basic EPS ₹16.40 ₹16.54 ₹15.07 ₹12.10 ₹15.52 ₹13.57 ₹14.67 ₹10.76 ₹11.48 ₹9.89 ₹12.84 ₹7.04
Diluted EPS ₹16.40 ₹17.45 ₹15.20 ₹12.10 ₹15.52 ₹13.57 ₹14.91 ₹10.76 ₹11.48 ₹2.70 ₹12.84 ₹7.81
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,790.2 Cr ₹3,723.49 Cr ₹3,407.25 Cr ₹3,216.34 Cr ₹3,217.51 Cr ₹3,193.73 Cr ₹3,224.68 Cr
Other Income ₹142.56 Cr ₹142.56 Cr ₹123.48 Cr ₹101.52 Cr ₹76.22 Cr ₹110.19 Cr ₹77.56 Cr
Total Income ₹3,932.76 Cr ₹3,866.05 Cr ₹3,530.73 Cr ₹3,317.86 Cr ₹3,293.73 Cr ₹3,303.92 Cr ₹3,302.24 Cr
Cost of Materials Consumed ₹400.07 Cr ₹470.86 Cr ₹504.99 Cr ₹394.35 Cr ₹552.47 Cr ₹452.64 Cr ₹474.38 Cr
Purchases of Stock-in-Trade ₹910.44 Cr ₹845.11 Cr ₹853.08 Cr ₹788.43 Cr ₹729.44 Cr ₹880.11 Cr ₹868.92 Cr
Changes in Inventories ₹13.5 Cr ₹51.23 Cr -₹69.64 Cr ₹67.25 Cr ₹13.83 Cr -₹27.53 Cr -₹35.43 Cr
Employee Benefit Expense ₹607.25 Cr ₹579.7 Cr ₹624.39 Cr ₹594.99 Cr ₹610.23 Cr ₹614.69 Cr ₹628.55 Cr
Finance Costs ₹2.73 Cr ₹1.31 Cr ₹1.8 Cr ₹1.81 Cr ₹1.99 Cr ₹3.53 Cr ₹6.34 Cr
Depreciation & Amortisation ₹66.44 Cr ₹66.79 Cr ₹69.68 Cr ₹65.77 Cr ₹68.19 Cr ₹79.28 Cr ₹82.68 Cr
Other Expenses ₹558.74 Cr ₹607.3 Cr ₹593.78 Cr ₹571.91 Cr ₹555.71 Cr ₹578.87 Cr ₹629.81 Cr
Total Expenses ₹2,559.17 Cr ₹2,622.3 Cr ₹2,578.08 Cr ₹2,484.51 Cr ₹2,531.86 Cr ₹2,581.59 Cr ₹2,655.24 Cr
Profit Before Exceptional Items & Tax ₹1,373.59 Cr ₹1,243.75 Cr ₹952.65 Cr ₹833.35 Cr ₹761.87 Cr ₹722.33 Cr ₹646.99 Cr
Exceptional Items ₹2.64 Cr ₹4.69 Cr -₹143.61 Cr -₹97 Lakh ₹11.58 Cr -₹172.6 Cr -₹324.49 Cr
Profit Before Tax ₹1,376.23 Cr ₹1,248.44 Cr ₹809.04 Cr ₹832.38 Cr ₹773.45 Cr ₹549.73 Cr ₹322.5 Cr
Total Tax Expense ₹364.41 Cr ₹329.38 Cr ₹224.35 Cr ₹227.68 Cr ₹396.87 Cr ₹192.17 Cr ₹212.45 Cr
Net Profit ₹1,011.82 Cr ₹919.06 Cr ₹584.69 Cr ₹607.75 Cr ₹1,690.53 Cr ₹357.56 Cr ₹110.05 Cr
Other Comprehensive Income -₹7.54 Cr -₹2.66 Cr -₹4.17 Cr -₹6.04 Cr -₹1.85 Cr -₹2.05 Cr -₹3.98 Cr
Total Comprehensive Income ₹1,004.28 Cr ₹916.4 Cr ₹580.52 Cr ₹601.71 Cr ₹1,688.68 Cr ₹355.51 Cr ₹106.08 Cr
EBITDA (computed) ₹1,442.76 Cr ₹1,311.85 Cr ₹1,024.13 Cr ₹900.93 Cr ₹832.05 Cr ₹805.14 Cr ₹736.01 Cr
Basic EPS ₹59.00 ₹54.01 ₹34.51 ₹35.70 ₹22.23 ₹21.11 ₹6.50
Diluted EPS ₹59.00 ₹54.24 ₹34.51 ₹35.70 ₹22.23 ₹21.11 ₹6.50
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,274.91 Cr ₹4,100.93 Cr ₹3,547.8 Cr ₹3,327.7 Cr
Non-current Assets ₹553.26 Cr ₹524.57 Cr ₹573.49 Cr ₹652.51 Cr
Current Assets ₹3,721.65 Cr ₹3,576.36 Cr ₹2,974.31 Cr ₹2,675.19 Cr
Property, Plant & Equipment ₹273.51 Cr ₹269.54 Cr ₹296.8 Cr ₹294.81 Cr
Inventories ₹430.35 Cr ₹463.17 Cr ₹514.3 Cr ₹437.7 Cr
Trade Receivables ₹273.11 Cr ₹292.55 Cr ₹222.06 Cr ₹192.38 Cr
Cash & Equivalents ₹1,065.82 Cr ₹536.22 Cr ₹62.15 Cr ₹29.74 Cr
Equity (Net Worth) ₹2,241.18 Cr ₹1,949.23 Cr ₹1,784.09 Cr ₹1,753 Cr
Equity Share Capital ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹1,757.1 Cr ₹1,900.81 Cr ₹1,510.95 Cr ₹1,317.02 Cr
Total Liabilities ₹2,033.73 Cr ₹2,151.7 Cr ₹1,763.71 Cr ₹1,574.7 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹881.42 Cr ₹1,280.03 Cr ₹578.93 Cr ₹487.94 Cr ₹819.8 Cr
Investing Cash Flow ₹385.25 Cr -₹36.54 Cr ₹14.97 Cr ₹805.19 Cr -₹419.66 Cr
Financing Cash Flow -₹737.07 Cr -₹769.42 Cr -₹561.49 Cr -₹1,544.18 Cr -₹524.25 Cr
Capital Expenditure ₹55.28 Cr ₹23.02 Cr ₹31.22 Cr ₹44.04 Cr ₹34.64 Cr
Free Cash Flow (computed) ₹826.14 Cr ₹1,257.01 Cr ₹547.71 Cr ₹443.9 Cr ₹785.16 Cr
Dividends Paid ₹713.97 Cr ₹749.38 Cr ₹541.57 Cr ₹1,525.5 Cr ₹506.64 Cr
Net Change in Cash ₹529.6 Cr ₹474.07 Cr ₹32.41 Cr -₹251.05 Cr -₹124.11 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹989.15 Cr ₹1,022.59 Cr ₹973.63 Cr ₹804.83 Cr ₹966.08 Cr ₹946.36 Cr ₹1,000.05 Cr ₹811 Cr ₹910.87 Cr ₹804.98 Cr ₹953.38 Cr ₹738.02 Cr
Other Income ₹35.71 Cr ₹31.82 Cr ₹31.27 Cr ₹43.76 Cr ₹39.46 Cr ₹35.06 Cr ₹32.19 Cr ₹35.85 Cr ₹29.87 Cr ₹28.34 Cr ₹28.47 Cr ₹36.8 Cr
Total Income ₹1,024.86 Cr ₹1,054.41 Cr ₹1,004.9 Cr ₹848.59 Cr ₹1,005.54 Cr ₹981.42 Cr ₹1,032.24 Cr ₹846.85 Cr ₹940.74 Cr ₹833.32 Cr ₹981.85 Cr ₹774.82 Cr
Cost of Materials Consumed ₹101.47 Cr ₹70.1 Cr ₹107.07 Cr ₹121.43 Cr ₹108.35 Cr ₹91.93 Cr ₹137.25 Cr ₹133.33 Cr ₹192.29 Cr ₹87.52 Cr ₹79.71 Cr ₹145.47 Cr
Purchases of Stock-in-Trade ₹228.39 Cr ₹217.27 Cr ₹232.71 Cr ₹232.07 Cr ₹291.4 Cr ₹164.23 Cr ₹216.74 Cr ₹172.74 Cr ₹255.74 Cr ₹162.52 Cr ₹260.62 Cr ₹174.2 Cr
Changes in Inventories ₹6.56 Cr ₹61.71 Cr ₹10.76 Cr -₹65.53 Cr -₹53.41 Cr ₹95.28 Cr ₹22.62 Cr -₹13.26 Cr -₹98.9 Cr ₹63.93 Cr ₹9.71 Cr -₹44.38 Cr
Employee Benefit Expense ₹164.75 Cr ₹151.88 Cr ₹138.05 Cr ₹152.57 Cr ₹152.97 Cr ₹124.74 Cr ₹150.71 Cr ₹151.28 Cr ₹172.83 Cr ₹141.35 Cr ₹145.21 Cr ₹165 Cr
Finance Costs ₹61 Lakh ₹1.19 Cr ₹51 Lakh ₹42 Lakh ₹58 Lakh ₹9 Lakh ₹27 Lakh ₹37 Lakh ₹77 Lakh ₹32 Lakh ₹43 Lakh ₹28 Lakh
Depreciation & Amortisation ₹13.17 Cr ₹20.32 Cr ₹17.43 Cr ₹15.52 Cr ₹14.72 Cr ₹18.8 Cr ₹16.86 Cr ₹16.41 Cr ₹18.1 Cr ₹17.11 Cr ₹18.11 Cr ₹16.36 Cr
Other Expenses ₹140.79 Cr ₹154.05 Cr ₹150.36 Cr ₹113.54 Cr ₹136.03 Cr ₹180 Cr ₹153.78 Cr ₹137.49 Cr ₹133.6 Cr ₹132.15 Cr ₹171.55 Cr ₹156.48 Cr
Total Expenses ₹655.74 Cr ₹676.52 Cr ₹656.89 Cr ₹570.02 Cr ₹650.64 Cr ₹675.07 Cr ₹698.23 Cr ₹598.36 Cr ₹674.43 Cr ₹604.9 Cr ₹685.34 Cr ₹613.41 Cr
Profit Before Exceptional Items & Tax ₹369.12 Cr ₹377.89 Cr ₹348.01 Cr ₹278.57 Cr ₹354.9 Cr ₹306.35 Cr ₹334.01 Cr ₹248.49 Cr ₹266.31 Cr ₹228.42 Cr ₹296.51 Cr ₹161.41 Cr
Exceptional Items ₹0 ₹0 ₹2.64 Cr ₹0 ₹0 ₹0 ₹4.69 Cr ₹0 ₹2.4 Cr -₹163.31 Cr ₹0 ₹17.3 Cr
Profit Before Tax ₹369.12 Cr ₹377.89 Cr ₹350.65 Cr ₹278.57 Cr ₹354.9 Cr ₹306.35 Cr ₹338.7 Cr ₹248.49 Cr ₹268.71 Cr ₹65.11 Cr ₹296.51 Cr ₹178.71 Cr
Total Tax Expense ₹94.18 Cr ₹100.71 Cr ₹95.65 Cr ₹73.87 Cr ₹94.76 Cr ₹77.77 Cr ₹90.01 Cr ₹66.84 Cr ₹75.63 Cr ₹19.62 Cr ₹80.97 Cr ₹48.13 Cr
Net Profit ₹274.94 Cr ₹277.18 Cr ₹255 Cr ₹204.7 Cr ₹260.14 Cr ₹228.58 Cr ₹248.69 Cr ₹181.65 Cr ₹193.08 Cr ₹45.49 Cr ₹215.54 Cr ₹130.58 Cr
Other Comprehensive Income -₹13.74 Cr ₹6.2 Cr ₹0 ₹0 -₹3.84 Cr ₹1.18 Cr ₹0 ₹0 -₹69 Lakh -₹3.48 Cr ₹0 ₹0
Total Comprehensive Income ₹261.2 Cr ₹283.38 Cr ₹255 Cr ₹204.7 Cr ₹256.3 Cr ₹229.76 Cr ₹248.69 Cr ₹181.65 Cr ₹192.39 Cr ₹42.01 Cr ₹215.54 Cr ₹130.58 Cr
EBITDA (computed) ₹382.9 Cr ₹399.4 Cr ₹365.95 Cr ₹294.51 Cr ₹370.2 Cr ₹325.24 Cr ₹351.14 Cr ₹265.27 Cr ₹285.18 Cr ₹245.85 Cr ₹315.05 Cr ₹178.05 Cr
Basic EPS ₹16.23 ₹16.36 ₹14.92 ₹12.08 ₹15.35 ₹13.49 ₹14.45 ₹10.72 ₹11.39 ₹9.88 ₹12.72 ₹6.94
Diluted EPS ₹16.22 ₹16.36 ₹15.06 ₹12.08 ₹15.35 ₹13.49 ₹14.68 ₹10.72 ₹11.39 ₹2.69 ₹12.72 ₹7.71
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Glaxosmithkline Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board & Governance of Glaxosmithkline Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Glaxosmithkline Pharmaceuticals Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Renu Sud Karnad.

DirectorPositionOn board sinceListed boards
Renu Sud Karnad Non-Executive - Non Independent Director · Chairperson 2019-04-01 5
Sunita Maheshwari Non-Executive - Independent Director 2020-05-18 2
Manu Anand Non-Executive - Independent Director 2022-05-16 2
Somasundaram Palamadairamaswamy Non-Executive - Independent Director 2025-03-26 2
Anup Wadhawan Non-Executive - Independent Director 2025-03-26 3
Bhushan Akshikar Executive Director 2022-12-01 1
Juby Chandy Executive Director 2022-04-01 1
Subesh Williams Non-Executive - Non Independent Director 2017-04-07 1
Board Committees
CommitteeMembers
Audit Committee Somasundaram Palamadairamaswamy (Chairperson), Manu Anand, Renu Sud Karnad
Nomination and remuneration committee Manu Anand (Chairperson), Anup Wadhawan, Renu Sud Karnad
Stakeholders Relationship Committee Renu Sud Karnad (Chairperson), Bhushan Akshikar, Sunita Maheshwari
Risk Management Committee Somasundaram Palamadairamaswamy (Chairperson), Manu Anand, Renu Sud Karnad
Corporate Social Responsibility Committee Sunita Maheshwari (Chairperson), Bhushan Akshikar, Anup Wadhawan

Charges & Borrowings of Glaxosmithkline Pharmaceuticals Limited

Open charges
₹21.87 Cr
Satisfied charges
₹130 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Ltd.₹21.87 Cr
Latest charge details
DateLenderAmountStatus
13 Jul 1989 The Hongkong and Shanghai Banking Corporation Ltd. ₹21.87 Cr Open
20 Sep 2004 Uti Bank Ltd. ₹130 Cr Satisfied

Total charge records: 2 View all charges

Employees and EPFO Compliance at Glaxosmithkline Pharmaceuticals Limited

View historical data on people associated with Glaxosmithkline Pharmaceuticals Limited, including employment history and EPFO contributions.

Premium access

Employee and EPFO history for Glaxosmithkline Pharmaceuticals Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Glaxosmithkline Pharmaceuticals Limited

Premium access

GST registrations and filing compliance for Glaxosmithkline Pharmaceuticals Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Glaxosmithkline Pharmaceuticals Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Glaxosmithkline Pharmaceuticals Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Glaxosmithkline Pharmaceuticals Limited

Premium access

MSME payment history for Glaxosmithkline Pharmaceuticals Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Glaxosmithkline Pharmaceuticals Limited

Premium access

Corporate group structure for Glaxosmithkline Pharmaceuticals Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Glaxosmithkline Pharmaceuticals Limited

Premium access

MCA filings and documents for Glaxosmithkline Pharmaceuticals Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Glaxosmithkline Pharmaceuticals Limited

Directors
30 Apr 2026
Ronojit Biswas was appointed as a Cfo on 30 Apr 2026 & has been associated with this company since 2 months 23 days.
Directors
01 Apr 2026
Ronojit Biswas was appointed as a Whole-Time Director on 01 Apr 2026 & has been associated with this company since 3 months 21 days.
Activity
27 Jun 2025
Glaxosmithkline Pharmaceuticals Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records.
Activity
31 Mar 2025
Glaxosmithkline Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
26 Mar 2025
Somasundaram Palamadairamaswamy was appointed as a Director on 26 Mar 2025 & has been associated with this company since 1 year 3 months.
Directors
26 Mar 2025
Anup Wadhawan was appointed as a Director on 26 Mar 2025 & has been associated with this company since 1 year 3 months.

Recent News on Glaxosmithkline Pharmaceuticals Limited

Frequently Asked Questions about Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 13 November 1924 (102+ years old) and is registered under CIN L24239MH1924PLC001151. Listed on BSE: 500660 and NSE: GLAXO. The company has 505 employees.

Glaxosmithkline Pharmaceuticals Limited reported revenue of ₹3,821.67 Cr for FY 2026 (up 1.93% YoY) based on consolidated NSE filings.

The current directors of Glaxosmithkline Pharmaceuticals Limited are:

The primary industry of Glaxosmithkline Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Glaxosmithkline Pharmaceuticals Limited is listed on both BSE (code: 500660) and NSE (symbol: GLAXO).

Glaxosmithkline Pharmaceuticals Limited can be reached at the registered office: Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030, or through the website india-pharma.gsk.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available